Questcor beats on EPS, beats on revenue

Questcor Pharmaceuticals (QCOR): Q2 EPS of $1.35 beats by $0.35.

Revenue of $196.1M beats by $27M. (PR)

Shares +10.3% AH.

From other sites
Comments (6)
  • EXPstocktrader
    , contributor
    Comments (388) | Send Message
    B A N G ....Shorts get smoked !!! Congrats longs....



    Peace, EXP
    30 Jul 2013, 04:40 PM Reply Like
    , contributor
    Comments (67) | Send Message
    Sweet indeed.
    30 Jul 2013, 04:52 PM Reply Like
  • Sammy Lee
    , contributor
    Comments (339) | Send Message
    Months ago I ran a screen with free cash flow yield as a primary filter and the two most prominent names that came was :


    1.) Apple
    2.) Questcor


    Missed it on Questcor.
    30 Jul 2013, 05:12 PM Reply Like
  • greganderson
    , contributor
    Comments (4) | Send Message
    To bad Michael Fuller isn't here to celebrate. He was probably the most effective analyst on QCOR but was banished for challenging the motives of some market "big boys." Really miss him.
    30 Jul 2013, 06:34 PM Reply Like
  • Michael Bryant
    , contributor
    Comments (7329) | Send Message
    Well, as I said long time ago, even if there is a generic version of (QCOR)'s drug in Europe, that does not affect the U.S., since the FDA has not approved any generic biotech drugs. It has no guidelines.
    30 Jul 2013, 11:47 PM Reply Like
  • Moderation
    , contributor
    Comments (723) | Send Message
    Chuck Carnevale got it right...
    31 Jul 2013, 12:23 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs